Levodopa/Carbidopa (Laxxon Medical)

N/A

Report date: 2025/12/08 13:47:09
NME

Base Information

Drug NameLevodopa/Carbidopa (Laxxon Medical)
Drug Alias NameLXM.5
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine receptors agonistsDOPA decarboxylase inhibitors
TargetsDopamine receptorsAromatic-L-amino-acid decarboxylase
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLaxxon Medical Corp
China Registration ClassN/A

Develop Information

Active CompaniesLaxxon Medical Corp
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A